Tier 3 — preclinical

Nicotinamide Riboside Opposes Type 2 Diabetes and Neuropathy in Mice

Trammell SA, Weidemann BJ, Chadda A, Yorek MS, Holmes A, Coppey LJ, Obrosov A, Kardon RH, Yorek MA, Brenner C
Scientific reports 2016 6; 26933

Bibliography

PubMed
PMID 27230286
PubMed Central
PMC4882590
DOI
10.1038/srep26933
Funding
Fraternal Order of Eagles Diabetes Research Center, Roy J. Carver Trust, NIH and US Department of Veterans Affairs support.
Competing interests
Disclosures include NR-related licensed intellectual property, research/advisory relationships with ChromaDex and a supplement-business advisory role.

Study snapshot

DesignPreclinical animal study with supporting assays as applicable
ModelMouse prediabetes and diabetes models
SamplePrediabetic and streptozotocin/high-fat-diet diabetic mice
InterventionNR added to the experimental diet
DurationDiet-induced disease and treatment protocols
EndpointsModel-specific physiological outcomes; Biochemical or functional measures reported in the study

What the study showed, in plain terms

NR improved selected glucose, liver and peripheral-nerve outcomes in the tested mouse diabetes models.

Key findings

NR improved selected glucose, liver and peripheral-nerve outcomes in the tested mouse diabetes models.

What this study can and cannot tell us

Disease induction, species and dose differ from human supplementation; later human studies must be considered separately.

Related papers in the corpus

Tier 3
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity
Cantó C et al. · Cell metabolism · 2012

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology